西班牙Certest輪狀病毒VP6重組蛋白

廣州健侖生物科技有限公司

廣州健侖長期供應各種生物原料，主要代理品牌：西班牙Certest。

主要產品包括各種生物單克隆抗原抗體、重組蛋白。

西班牙Certest輪狀病毒VP6重組蛋白

我司還提供其它進口或國產試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產品。

歡迎咨詢

歡迎咨詢2042552662

【產品介紹】

西班牙Certest輪狀病毒VP6重組蛋白

PSCC主要風險因素是使用煙草和酒精。zui近，人類抗原抗體狀瘤病毒(HPV)已被證明參與口咽鱗狀細胞癌的發展和預后，許多醫院定期測試患者HPV。迄今還沒有其他明顯的標志物可預示PSCC病人的生存。
這是*項研究評估EMT相關轉錄因子在PSCC的作用。上皮間質轉化(EMT)是一個復雜的細胞過程，不僅對于胚胎發育是至關重要的，同時它也在腫瘤進展中被活化，從而使腫瘤細胞變得侵入性增強并引發轉移。一些轉錄因子如SNAI1，TWIST，SIP1，SLUG和ZEB1是調節EMT的根本因子。
本研究*評估PSCC中EMT相關的轉錄因子的作用。對上皮腫瘤細胞，基質細胞和內皮細胞的細胞核轉錄因子SNAI1，TWIST，SIP1，SLUG和ZEB1的免??疫組化表達進行分析，以評估臨床病理學變量與患者聯預后的關系。
有上皮腫瘤細胞核SIP1染色陽性的腫瘤更晚期。有更多的淋巴結轉移。內皮細胞中表達SNAI1預示患者存活率降低，腫瘤大小增加。而基質細胞TWIST表達與高復發風險有。
病人和醫生往往不知道手術切除癌變組織后是否很成功，直到手術幾個月后再進行掃描時才能知道。現在，一種新的納米顆粒可以更早地顯示患者在手術后是否成功切除了全部癌變組織。
這種納米顆粒被稱為納米耀斑(nanoflares)。在實驗時，顆粒會依附于血液樣品中的每一個單獨的癌細胞上，然后會發光。通過激光的輔助可以檢測到癌細胞或對其分類。因為有很多不同類型的癌細胞，其中有一些癌細胞遠遠比其他的更加致命，通過使用這個技術可以檢測到這些更致命癌細胞并采集它們，因為這些細胞在采集之后還可以在培養皿中進行培養，用納米顆粒還可以在給病人真正治療前，更容易地測試一些潛在的治療方案。
研究人員表明，目前該納米顆粒可檢測小鼠不同類型的抗原抗體癌細胞。他們還表明，納米顆粒在添加進人類血液后也能識別出抗原抗體癌細胞。他們下一步是確定該顆粒能否從患者體內提取的血液樣本中發現癌細胞。
每個納米耀斑都是由金色涂層的熒光微粒與DNA片斷共同組成的。DNA被選擇為對應于在特定的癌癥細胞中發現的RNA。一旦引入到血液樣本中，納米顆粒就會進入癌細胞而且納米顆粒的DNA將結合到靶RNA上，從而觸發熒光微粒的釋放，從而導致癌細胞發光。可以通過將不同的DNA的片段與不同顏色熒光微粒和結合來檢測不同類型的癌細胞。

西班牙

想了解更多的產品及服務請掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司
【市場部】    楊永漢

【】 
【騰訊  】 2042552662
【公司地址】 廣州清華科技園創新基地番禺石樓鎮創啟路63號二期2幢101-103室

The main risk factor for PSCC is the use of tobacco and alcohol. Recently, the human antigens antibody tumor virus (HPV) has been shown to be involved in the development and prognosis of oropharyngeal squamous cell carcinoma, and many hospitals regularly test patients for HPV. To date there are no other significant markers that predict the survival of PSCC patients.
This is the first study assessing the role of EMT-related transcription factors in PSCC. Epithelial-mesenchymal transition (EMT) is a complex cellular process that is not only crucial for embryonic development, but also is activated during tumor progression so that tumor cells become more invasive and trigger metastases. Some transcription factors such as SNAI1, TWIST, SIP1, SLUG and ZEB1 are fundamental factors that regulate EMT.
This study is the first to assess the role of EMT-related transcription factors in PSCC. Immunohistochemical expression of the nuclear transcription factors SNAI1, TWIST, SIP1, SLUG and ZEB1 in epithelial tumor cells, stromal cells and endothelial cells was analyzed to assess the relationship between clinicopathological variables and patient prognosis.
SIP1-positive tumors with epithelial tumor nuclei are more advanced. There are more lymph node metastases. The expression of SNAI1 in endothelial cells predicts a decrease in patient survival and an increase in tumor size. The expression of stromal cells TWIST is associated with a high risk of recurrence.
Patients and doctors often do not know whether successful surgical resection of cancerous tissue is successful until a few months after the surgery before scanning. Now, a new nanoparticle can show earlier whether the patient successfully resected all of the cancerous tissue after surgery.
This type of nanoparticle is called nanoflares. During the experiment, the particles attach to each individual cancer cell in the blood sample and then glow. Cancer cells can be detected or classified by the help of laser. Because there are many different types of cancer cells, some of which are far more lethal than others, these more deadly cancer cells can be detected and harvested using this technique because they can also be collected in a Petri dish For incubation, using nanoparticles also makes it easier to test some potential treatment options before actually treating the patient.
Researchers have shown that at present the nanoparticles can detect different types of antigens in mice antibody cancer cells. They also show that nanoparticles can also recognize antigen-presenting cancer cells when added to human blood. Their next step is to determine if the particle can find cancer cells in blood samples taken from the patient's body.
Each nano-flare is composed of gold-coated fluorescent particles and DNA segments. The DNA is chosen to correspond to the RNA found in a particular cancer cell. Once introduced into the blood sample, the nanoparticles enter the cancer cells and the DNA of the nanoparticles will bind to the target RNA, triggering the release of fluorescent microparticles, causing the cancer cells to emit light. Different types of cancer cells can be detected by binding different fragments of DNA to different colored fluorescent particles.